On September 22, 2026 Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, reported it will host a virtual key opinion leader (KOL) event on Monday, October 5, 2026 at 8:00 AM ET featuring Oladapo Yeku, M.D., Ph.D., FACP (Harvard Medical School, Massachusetts General Hospital), who will join company management to discuss COM701 and the evolving treatment landscape in ovarian cancer. To register, click here.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Yeku will preview the randomized MAIA-ovarian adaptive platform trial design of COM701, a potential first-in-class anti-PVRIG antibody, evaluating safety and efficacy in the maintenance treatment of relapsed platinum sensitive ovarian cancer (PSOC), with median progression-free survival data from the interim analysis expected by Q1 2027.
Compugen’s Research and Discovery team will also provide an update on expanded capabilities of Unigen, its AI/ML-powered target discovery platform, which enables the discovery of novel cancer immunotherapy drug targets and the continuous advancement of the next generation of immuno-oncology innovation.
A live question and answer session will follow the formal presentations.
About Oladapo Yeku, MD, PhD, FACP
Dr. Oladapo Yeku is an Associate Professor of Medicine at Harvard Medical School and the Director of Translational Research for the Gynecologic Oncology Program at Massachusetts General Hospital. He is a Vice Chair of the Mass General Brigham Institutional Review Board and an Associate Editor at NEJM Evidence. Dr. Yeku completed his Medical Oncology fellowship training at Memorial Sloan Kettering Cancer Center (MSKCC) and is an expert on immunotherapy for gynecologic cancers. Dr. Yeku is actively involved as a Principal Investigator in early-phase drug development and adoptive cellular therapy clinical trials. His laboratory studies the immunosuppressive tumor microenvironment in Gynecologic Cancers and develops immunotherapeutic approaches such as Antibody Drug Conjugates (ADC), Bispecific T-cell Engagers, and Chimeric Antigen Receptor (CAR) T-cells to overcome these obstacles.
About COM701
COM701 is Compugen’s potential first-in-class anti-PVRIG antibody, a novel immune checkpoint identified through Compugen’s computational discovery platform. COM701 has been evaluated in Phase 1 clinical studies as monotherapy and in combination, with data demonstrating initial signs of anti-tumor activity and a favorable safety and tolerability profile. COM701 is currently being evaluated in the randomized MAIA-ovarian adaptive platform trial as a maintenance therapy in patients with relapsed platinum-sensitive ovarian cancer.
(Press release, Compugen, SEP 22, 2026, View Source;Unigen-Platform-Update-on-October-5-2026/default.aspx [SID1234670995])